RU94045248A - Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo - Google Patents

Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo

Info

Publication number
RU94045248A
RU94045248A RU94045248/14A RU94045248A RU94045248A RU 94045248 A RU94045248 A RU 94045248A RU 94045248/14 A RU94045248/14 A RU 94045248/14A RU 94045248 A RU94045248 A RU 94045248A RU 94045248 A RU94045248 A RU 94045248A
Authority
RU
Russia
Prior art keywords
vivo
virus
inhibition
activation
human
Prior art date
Application number
RU94045248/14A
Other languages
English (en)
Other versions
RU2145856C1 (ru
Inventor
Х. Дэвис Майкл
Us]
Original Assignee
Х. Дэвис Майкл
Us]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Дэвис Майкл, Us] filed Critical Х. Дэвис Майкл
Publication of RU94045248A publication Critical patent/RU94045248A/ru
Application granted granted Critical
Publication of RU2145856C1 publication Critical patent/RU2145856C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Метод ингибирования активности человеческого вируса иммунодефицита (HIV) in vivo включает прием человеком-носителем антималярийного средства, которое способно проявлять защитный эффект, целебный эффект или предотвращать передачу малярии у людей. Антималярийное средство выбирается из группы, состоящей из 4-аминохинолинов, принимается человеком в количестве, достаточном для предотвращения или по меньшей мере ингибирования инфекции Т-лимфоцитов вирусом HIV in vivo или для предотвращения или по меньшей мере ингибирования репликации HIV in vivo.

Claims (1)

  1. Метод ингибирования активности человеческого вируса иммунодефицита (HIV) in vivo включает прием человеком-носителем антималярийного средства, которое способно проявлять защитный эффект, целебный эффект или предотвращать передачу малярии у людей. Антималярийное средство выбирается из группы, состоящей из 4-аминохинолинов, принимается человеком в количестве, достаточном для предотвращения или по меньшей мере ингибирования инфекции Т-лимфоцитов вирусом HIV in vivo или для предотвращения или по меньшей мере ингибирования репликации HIV in vivo.
RU94045248A 1988-06-30 1989-06-19 Способ предотвращения или ингибирования инфицирования т-лимфоцитов человеческим вирусом иммунодефицита (hiv) и репликации in vivo RU2145856C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21382288A 1988-06-30 1988-06-30
US213822 1988-06-30
PCT/US1989/002586 WO1990000055A1 (en) 1988-06-30 1989-06-19 Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo

Publications (2)

Publication Number Publication Date
RU94045248A true RU94045248A (ru) 1996-08-20
RU2145856C1 RU2145856C1 (ru) 2000-02-27

Family

ID=22796649

Family Applications (2)

Application Number Title Priority Date Filing Date
RU94045248A RU2145856C1 (ru) 1988-06-30 1989-06-19 Способ предотвращения или ингибирования инфицирования т-лимфоцитов человеческим вирусом иммунодефицита (hiv) и репликации in vivo
SU894894541A RU2060032C1 (ru) 1988-06-30 1989-06-19 Способ ингибирования активности вируса иммунодефицита человека - hjv in vivo в эксперименте

Family Applications After (1)

Application Number Title Priority Date Filing Date
SU894894541A RU2060032C1 (ru) 1988-06-30 1989-06-19 Способ ингибирования активности вируса иммунодефицита человека - hjv in vivo в эксперименте

Country Status (9)

Country Link
EP (1) EP0422097B1 (ru)
JP (1) JPH03505579A (ru)
KR (1) KR920008704B1 (ru)
AT (1) ATE104851T1 (ru)
AU (1) AU633499B2 (ru)
BR (1) BR8907518A (ru)
DE (1) DE68914990T2 (ru)
RU (2) RU2145856C1 (ru)
WO (1) WO1990000055A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668149A (en) * 1990-01-26 1997-09-16 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of human immunodeficiency virus-1 infectivity in human cells
CA2094139A1 (en) * 1990-10-22 1992-04-23 Frederick W. Wassmundt Aryl and heteroaryl compounds having anti-retrovirus activity
MX9204103A (es) * 1991-07-15 1993-02-01 Smithkline Beecham Plc Halogenofantrina, sus sales y composiciones que las contienen.
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
ITBO20020416A1 (it) * 2002-06-28 2003-12-29 Valpharma Sa Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti
US7772284B2 (en) * 2003-08-27 2010-08-10 Labib Mohamed E Method for the treatment or prevention of virus infection using polybiguanide-based compounds
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
KR102205202B1 (ko) * 2013-02-01 2021-01-21 웰스태트 테러퓨틱스 코포레이션 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물
WO2020035880A1 (en) * 2018-08-13 2020-02-20 National Centre For Biological Sciences-Tifr Inhibitors to target hiv-1 nef-cd80/cd86 interactions for therapeutic intervention

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005755A (en) * 1956-03-30 1961-10-24 Endo Lab Aqueous solutions of quinidine salts and nicotinamide
AU596272B2 (en) * 1987-02-25 1990-04-26 Trustees Of Columbia University In The City Of New York, The Method of inhibiting the transmission of aids virus
JPH01221364A (ja) * 1988-01-11 1989-09-04 Microbial Chem Res Found Ｈｉｖ逆転写酵素阻害剤および抗腫瘍剤

Also Published As

Publication number Publication date
EP0422097A4 (en) 1992-03-11
KR900701271A (ko) 1990-12-01
EP0422097B1 (en) 1994-04-27
DE68914990D1 (de) 1994-06-01
JPH03505579A (ja) 1991-12-05
DE68914990T2 (de) 1994-08-11
BR8907518A (pt) 1991-05-28
EP0422097A1 (en) 1991-04-17
AU633499B2 (en) 1993-02-04
RU2060032C1 (ru) 1996-05-20
ATE104851T1 (de) 1994-05-15
RU2145856C1 (ru) 2000-02-27
AU3852989A (en) 1990-01-23
KR920008704B1 (ko) 1992-10-08
WO1990000055A1 (en) 1990-01-11

Similar Documents

Publication Publication Date Title
UA40589C2 (ru) способ лечения человека, страдающего от вирусной инфекции, фармацевтическая композиция, комбинация веществ для получения лекарств и фармацевтическая комбинация
EP0270317A3 (en) Pharmaceutical compositions for the treatment of diseases caused by viruses
CA2067381A1 (en) Treatment of hiv infections and compounds useful therein
NO922936L (no) Fremstilling av fettsyremedikamenter
UA35567C2 (ru) Фармацевтический препарат для лечения больных с нарушениями функции коагуляции, способ лечения этих больных, способ получения фармацевтического препарата
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
RU94045248A (ru) Способ ингибирования активности вируса иммунодефицита человека (hiv) in vivo
ES2128043T3 (es) Uso de bis(amidinobencimidazoles) en la preparacion de un medicamento para inhibir la integrasa retroviral.
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
CA2068327A1 (en) Polypeptide and anti-hiv drug prepared therefrom
DK561089A (da) Anvendelse af lactamimider til fremstilling af laegemidler
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
WO1990013281A3 (en) Method of suppressing hiv infection
SE9303853L (sv) Användning av en inositoltrisfosfatester för beredning av läkemedel
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
CA2189705A1 (en) Use of flupirtine for the prophylaxis and therapy of diseases associated with an impairment of the haematopoetic cell system
EP0601183A4 (en) ANTI-HIV MEDICINE.
FR2613617B1 (fr) Agents medicamenteux pour la prevention et la therapie des brulures cutanees par rayons, contenant comme principe actif la 2,6-dimethyl-3,5-diethoxycarbonyl-1,4-dihydropyridine
UA42693C2 (ru) Лекарственное средство для лечения инфекции лентивирусом, препарат для лечения человека, который инфицирован лентивирусом
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
DK0910405T3 (da) Vaccine, som indeholder caprint arthritis-encephalitis-virus, og anvendelse til immunbeskyttelse imod HIV-1-infektion
CA2032748A1 (en) Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo
AU2396900A (en) Treatment and prevention of hiv and other viral infections

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20070620